Bayer Aktiengesellschaft (BAYN) Earnings Call Transcript & Summary

February 27, 2020

Deutsche Boerse Xetra DE Health Care Pharmaceuticals earnings 107 min

Earnings Call Speaker Segments

Michael Preuss

executive
#1

Good morning, ladies and gentlemen, and welcome to our financial news conference. <<inaudible>> financial news conference here at the Baykomm in Leverkusen. And to follow the news conference, please choose channel #2 on your translation device. <<interpreted>> It's wonderful that you're here in Leverkusen this morning. Thank you for coming. And also against the backdrop around the coronavirus, as you may have heard, there is a suspected case here in Leverkusen. One of our employees here may be infected with the virus, but I've just heard good news that this has not been confirmed. The employee has not been confirmed as suffering from the coronavirus. Nonetheless, I hope that she gets well real soon. Now nonetheless, we've discussed this intensely also considering corona, and we thought about whether this should be a live news conference or should it be a webcast. We decided that since the assessment of the authorities is as it is, we decided to have a live news conference. We also have journalists who are not with us here in person. They're following us by webcast, and they will also be able to ask questions by webcast. So I'd like to welcome them here as well too.

Michael Preuss

executive
#2

Setting all that aside, this press conference is being held in this room at the Baykomm for the first time, and I hope you feel at home here. We also want this event to run without any interruptions, so please turn off your cellphones. As you know, the Board at Bayer AG now has 5 members, and I'd like to introduce them and explain what each is responsible for. I'll start with Liam Condon. He heads the Crop Science division. For Liam, having a press conference makes this a very special day. It's his birthday too. And he enjoyed himself so much here on his birthday last year that we decided to celebrate it again with a great press conference. All the very best to you. Happy birthday, Liam. Then I'd like to welcome the CEO at Bayer AG, Werner Baumann. He has also taken on responsibility for HR and sustainability. He is also Labor Director at labor AG (sic) Bayer AG. And then we have Wolfgang Nickl. He is the CFO at Bayer AG. And beside him, we have Stefan Oelrich.

Michael Preuss

executive
#3

The Pharmaceuticals division is led by him. And Heiko Schipper as well. Consumer Health falls under his responsibility. Those, then, are the Board members. Now I'll explain how the news conference will unfold. Our CEO, Werner Baumann, will be speaking to us. Business in 2019 will be summarized by him, and he will discuss what our focus will be in 2020. Our CFO, Wolfgang Nickl, will then speak. More detail on the KPIs will come from him, along with an outlook for 2020. Following that, the whole Board will be on hand to take any questions you may have. So at this point I would like to pass things over to Werner Baumann.

Werner Baumann

executive
#4

Thank you so much, Michael. Ladies and gentlemen, welcome to our financial news conference here in Baykomm, and that welcome also comes from the members of the Board. We're very pleased to present our 2019 results to you, and naturally, we're looking forward to answering all your questions afterward. Looking back at 2019 today, I would put it this way: 2019 can be described in just a few words — we have delivered. You'll recall that a little over a year ago, in December 2018, we held our Capital Markets Day. There we communicated ambitious targets and discussed strategic levers such as sustainability. Just before that Capital Markets Day, we had announced an extensive package of measures concerning our portfolio, our structures and our efficiencies, aimed at putting Bayer in a good position for the future. Now, a little more than a year later, I can say that we have made good on all of our promises. That applies first of all to the operational business. We achieved our financial targets last year despite a very challenging market environment, particularly in the agricultural sector — but I'll go into more detail on that later.

Werner Baumann

executive
#5

We also followed through on the portfolio actions we announced. Our Animal Health business is being sold to Elanco for $7.6 billion, and we expect that deal to close in mid-2020. In 2019, we also successfully divested our stake in the site services provider Currenta and sold off Dr. Scholl's and Coppertone as well. All of these portfolio measures were announced in December 2018, and we were actually able to implement them earlier than expected. And even more importantly, the divestment proceeds were in some cases very attractive for our company. We also delivered on the efficiency and structural measures. Wolfgang Nickl will give you an update on this shortly regarding the implementation status of our ongoing programs. He'll also go into a little more detail about the progress that we've made with the integration of our agricultural business in 2019. We had also already spoken about the importance of sustainability when we completed the acquisition in 2018. We said we would apply the same determination to achieving our sustainability goals as we do to reaching our financial targets, and here too we have delivered. We considerably stepped up our sustainability efforts in 2019 and set ourselves ambitious targets, and I shall also go into more detail about these issues later.

Werner Baumann

executive
#6

But at the same time, 2019 demonstrated what sets us apart as a science company. We are convinced that our products, our scientific know-how and our capacity for innovation—the innovative strength of our people—enable us to make a genuine difference in people's lives. That is the reason we put EUR 5.3 billion into research and development last year. And that, by the way, is a record amount. For more than 150 years, Bayer has been a science-based company, yet never has such a large sum gone into research and development as in the past year. Today, naturally, our main focus is on the financial targets, so let me turn directly to how our business developed last year. In 2019, the Bayer Group recorded sales of EUR 43.5 billion. After adjusting for special items, EBITDA—our earnings before interest, taxes, depreciation and amortization—came to EUR 11.5 billion, the highest level Bayer has ever reached. On the slide, you can see double-digit growth relative to 2018. And a key factor here, of course, is that the former Monsanto business has been part of Bayer since June 2018. As a result, 2019 marked the first time the acquired business was included in Crop Science for a full year, yet even setting this effect aside, we can see substantial progress.

Werner Baumann

executive
#7

Revenue climbed 3.5% once you strip out currency and portfolio impacts. EBIT rose to EUR 4.2 billion, following net special charges of EUR 2.8 billion. Core earnings per share in 2019 climbed to EUR 6.40, powered by the earnings contribution from the acquired agricultural — agriculture business plus favorable business development at Pharmaceuticals. Wolfgang Nickl is going to walk you through those business developments shortly. Before that, though, I want to revisit the forecasts we laid out for 2019 and check what we actually delivered against them. Precisely a year ago, we announced our financial targets for 2019. Back then, those targets still encompassed the business units Animal Health and the interest in Currenta, Coppertone and Dr. Scholl's. After the sale of these businesses was agreed during the year, we revised the full year forecasts in October to account for these technical effects, setting them on the prevailing exchange rates. Today we can state that we have indeed met all of these targets. That means we can place 3 green ticks next to our 3 key indicators: sales, EBITDA before special items and core earnings per share.

Werner Baumann

executive
#8

And I'd say this is really welcome news, particularly considering the headwinds we've run into. Take, for instance, the fallout from the trade dispute pitting the U.S.A. against China, or the severe climate and weather occurrences around the globe, which hit our customers' harvests directly and, by extension, our own business too. So in brief, we held up quite well amid a tough environment. For Bayer, the results we're sharing with you today send an important signal about our operational strength, and they also show the reliability of our whole organization. Naturally, we'll also make sure our stockholders get a proper share of this success, which is why we're proposing to the Annual Stockholders' Meeting a dividend of EUR 2.8 per share for 2019. At roughly 44% of core earnings per share, the dividend payout ratio sits above the 30% to 40% target corridor, and it likewise reflects the success of the portfolio measures for our owners. That now brings us to the divisional figures, and Wolfgang is going to walk us through those.

Wolfgang Nickl

executive
#9

Thanks so much, Werner. And a warm welcome from me as well, here in Leverkusen, ladies and gentlemen. Before I go into the business developments and the divisions for 2019 overall, I'd like to give you a brief report on the fourth-quarter figures. Then I'll comment on a few other indicators for 2019, and I'll also discuss the forecast for the current year. Please note that whenever I speak of sales and sales growth, I'm referring to results adjusted for currency and portfolio effects. Group sales in the fourth quarter came in at EUR 10.8 billion. That's up 3.4% against the prior year period, so overall the business developed positively in the fourth quarter. EBITDA before special items also moved higher, reaching EUR 2.5 billion. That's an increase of 26.4%. Our agricultural and pharmaceutical businesses in particular achieved significant earnings growth. Core earnings per share advanced by 22.9% in the fourth quarter to EUR 1.29. Now I'll explain how the divisions' businesses developed over the full year. Let's start with our agriculture business. The Crop Science division posted sales of EUR 19.8 billion last year. That's an increase of 1.4%.

Wolfgang Nickl

executive
#10

When it comes to Crop Science, the main driver of sales growth was favorable business trends in Latin America. In that region, revenue increased 9.4% to EUR 5.1 billion, largely because of higher prices and greater volumes for Fungicides in Brazil. North American business matched the previous year's level, even with unfavorable weather in the Midwestern United States during the first half of the year. In that market, Corn Seed & Traits performed well. Sales declined, though, across the Europe, Middle East, Africa and Asia Pacific regions. Drought periods in countries like Australia, together with African swine fever, were among the factors behind that negative sales trend. At Crop Science, EBITDA before special items rose roughly 81% in 2019, reaching EUR 4.8 billion. That gain came mainly from the earnings contribution of the acquired business and from cost synergies related to integration. At the same time, several factors worked in the opposite direction: the missing earnings contribution from the businesses divested to BASF, a higher cost of goods sold, an unfavorable currency impact of EUR 24 million, and the weather conditions I mentioned earlier. Let's now turn to Pharmaceuticals. At this division, sales increased 5.6% in 2019, reaching EUR 18 billion.

Wolfgang Nickl

executive
#11

On one side, the key factors were sustained robust expansion in China; on the other, higher sales for Xarelto, our anticoagulant, and Eylea, the eye medicine. The radiology segment’s encouraging performance also contributed positively. Xarelto sales climbed sharply once more, reaching EUR 4.1 billion. This represented roughly a 13% gain versus the previous year, driven chiefly by greater volumes in China, Russia and Europe. With Eylea too, we posted an increase of about 13% in sales, to EUR 2.5 billion. Growth came mainly in the Europe, Middle East, Africa regions — particularly the United Kingdom and Germany. Japan likewise added to the higher sales. EBITDA before special items for Pharmaceuticals increased 6.7% in 2019, to EUR 6 billion. This favorable earnings trend stemmed primarily from larger volumes and reduced cost of goods sold. However, earnings were reduced by greater selling expenses tied to product launches and new indications, as well as an adverse currency impact of EUR 32 million. Turning now to Consumer Health: revenue from our self-care products increased 2.6% in 2019, to EUR 5.5 billion. In North America, after a soft first half, we began to see a recovery during the second half of the year.

Wolfgang Nickl

executive
#12

We achieved nice growth, particularly within allergy and cold, driven by larger volumes for Claritin, our antihistamine. Across the remaining regions, we managed to expand the business, helped partly by an improved supply situation. At Consumer Health, EBITDA before special items for 2019 matched the prior year, coming in at EUR 1.1 billion. Profit got a particular boost from rolling out our efficiency program, which brought selling expenses down. On top of that, we booked a favorable currency impact of EUR 16 million. Results were constrained by the missing contribution of the prescription dermatology business we divested. Now I would like to walk you through a few more financial indicators for the Bayer Group covering the full year 2019. Let's begin with cash flow. Operating cash flow rose to EUR 8.2 billion in 2019 from EUR 7.9 billion in 2018. Spending on property, plant and equipment as well as intangible assets was up only slightly versus a year earlier. Net interest payments, in contrast, climbed substantially. All told, free cash flow for the past year reached EUR 4.2 billion. That is comfortably ahead of the EUR 3 billion to EUR 4 billion range we had initially expected. The decrease relative to the prior year stems chiefly from the fact that 2019 free cash flow carries 12 months of acquisition-related financing costs, versus just 6 months a year earlier.

Wolfgang Nickl

executive
#13

With that in mind, we feel quite good about how free cash flow developed. The same holds true for net financial debt, which came to EUR 34.1 billion at the close of last year. That figure was EUR 1.6 billion lower than at the end of 2018. On one side stood cash coming in from operations and from divestments; on the other stood outflows for dividend payments, negative currency effects, and the impact of IFRS 16, the new financial reporting standard applied for the first time. The chief effect of that first-time application was the addition of roughly EUR 900 million in lease liabilities. Quickly reducing leverage on our statement of financial position will keep the same priority it had before. Total assets held at roughly the prior-year level, reaching EUR 126.3 billion on December 31, 2019. Equity climbed by EUR 1.4 billion versus the previous year, to EUR 47.5 billion, driven largely by the rise in total comprehensive income. As of December 31, 2019, the equity ratio increased to approximately 38%. The debt ratio fell correspondingly, from around 64% to around 62%. The primary effects stemmed from redeeming bonds and from selling our stake in Currenta, along with the related derecognition of pension provisions.

Wolfgang Nickl

executive
#14

Let me now turn to the progress we've made in rolling out our efficiency and structural initiatives. As we've previously announced, those measures are anticipated to deliver gross annual contributions of EUR 2.6 billion starting in 2022, and that figure includes the synergies we plan to gain from integrating the agriculture business. By 2019, 30% of that amount had already been reached. At Crop Science, both on the cost side and with the synergies, we're moving ahead more quickly than we had planned, and the same holds for our other efficiency and structural measures. Given this, we can now reaffirm the savings targets for 2022 that we set out earlier. Some of the resources this frees up will go toward further strengthening our potential for growth and our capacity for innovation. To illustrate, between 2019 and 2022 we intend to invest well over EUR 30 billion in the company's future, and more than 2/3 of that will be directed to research and development. Ladies and gentlemen, let me now proceed to our expectations and forecast for the current year and the current — the forecast for 2020. We are confident that our company will again achieve profitable growth this year. With that as a basis, we anticipate positive development in our key financial indicators.

Wolfgang Nickl

executive
#15

We've tweaked the currency-related forecasts so the comparison is cleaner. Sales for this year, we believe, will land somewhere between EUR 44 billion and EUR 45 billion. Once you strip out portfolio changes and currency effects, that works out to growth somewhere in the 3% to 4% range. For 2020, EBITDA before special items should rise significantly, reaching a figure somewhere between EUR 12.3 billion and EUR 12.6 billion. That would push the EBITDA margin before special items up to roughly 28%. As for core earnings per share, we anticipate a result this year of between EUR 7 and EUR 7.20, which lines up with an expected earnings-per-share gain of as much as 13%. Keep in mind this assumption rests on constant exchange rates and mirrors our current continuing operations, with Animal Health excluded. Thanks to a strong operational performance, free cash flow should climb to roughly EUR 5 billion. That amounts to a rise of around 19%. This forecast makes plain that our intention is to keep growing past 2019, and that is precisely what we laid out at the Capital Markets Day a little more than a year ago. Turning to the divisions, our agriculture business should move ahead by roughly 4% once currency and portfolio effects are adjusted for.

Wolfgang Nickl

executive
#16

We expect additional synergies from the business we acquired, plus sales growth from new products and a rebound in North America after the unfavorable weather in 2019. In Pharmaceuticals, we're forecasting adjusted sales growth between 3% and 4%, still propelled by higher Xarelto and Eylea sales. For Consumer Health, we anticipate sales rising between 2% and 3% in 2020, adjusted for currency and portfolio effects. Every region will play a part in that growth. Let's now turn to the EBITDA margin before special items by division. Because of portfolio changes and a major simplification of our internal processes, we've adjusted the group's value flows for 2020. So that comparability is ensured, we have likewise adjusted the 29 (sic) 2019 results to reflect this new method. In 2020, we expect EBITDA margins before special items and currency effects to improve across all divisions, in some cases substantially. Before I wrap up, I'd like to note that our forecast does not include any estimates of the potential effects of the coronavirus outbreak. Our initial focus in recent weeks has been on humanitarian aid for people in China. We've donated important medicines, and our colleagues in China have helped make sure the donations reach doctors and hospitals.

Wolfgang Nickl

executive
#17

Seeing our products help in the battle against the coronavirus is encouraging. Once the first quarter has ended, we'll be in a position to evaluate how the outbreak may affect our business. With that said, thank you for listening, and I'll turn things back over to you, Werner.

Werner Baumann

executive
#18

Thank you so much, Wolfgang. Ladies and gentlemen, as you're aware, the litigation regarding our glyphosate active ingredient was unfortunately one of the main topics at Bayer in 2019, even though we would have preferred otherwise, so allow me to give you a brief summary of where things stand right now. First, glyphosate has always been safe when used as directed, and that remains true today. Leading regulatory authorities around the world have confirmed this repeatedly. As recently as January 2020, the U.S. Environmental Protection Agency, the EPA, announced the findings of a new safety evaluation of glyphosate, which was based on an expert review process spanning more than 10 years. And the EPA once again reached the conclusion that — and I quote — "It did not identify any human health risks from exposure to glyphosate." The count of lawsuits concerning glyphosate has climbed again over recent months, and as of February 6, 2020, suits from approximately 48,600 plaintiffs have been served in the United States. In October last year, that figure stood at around 42,700. As you know, 3 trial juries in California have now ruled in favor of the respective plaintiffs at first instance. Not one of these verdicts is final.

Werner Baumann

executive
#19

At present, all 3 cases are going through appeal proceedings. In a recent court filing regarding 1 of the trials, the U.S. government voiced clear backing for central parts of the reasoning we have put forward. As I noted earlier, we will take the 3 appeals through every judicial instance, should that prove necessary. Alongside this robust courtroom defense, Bayer keeps engaging constructively in the mediation proceedings that are ongoing. Recent weeks have brought a great deal of speculation regarding what a possible settlement might look like, when it might come and how much it might be worth. You will surely appreciate that we have no wish to take part in that kind of speculation. Confidentiality of the discussions has been agreed by the parties, and we are naturally honoring that agreement. On the subject of U.S. litigations, I would also like to say a few brief words about dicamba. We do not agree with the jury verdict on dicamba that came down about 2 weeks ago and will appeal this decision promptly. At Bayer, naturally, we understand very well what crop losses mean to a farmer. Numerous employees in our Crop Science division work day in, day out to prevent precisely that. Yet in these legal proceedings, no competent evidence was presented showing that dicamba was present at all on the farm concerned or that it was to blame for the crop losses.

Werner Baumann

executive
#20

So because of that, we will now act in line with that and file an appeal against the ruling. Ladies and gentlemen, at Bayer last year, sustainability was a key subject. We engaged with this issue very thoroughly, asking ourselves what a company of our size — one that holds such an important role in fields like health and nutrition that matter so centrally to people — can do in order to contribute even more to sustainable development. We gave concrete answers in December, when we announced a comprehensive set of measures along with sustainability targets that I consider ambitious. We had a very solid basis to build on. The Carbon Disclosure Project has just awarded us its highest rating yet again, in both the climate change and the water security categories, and by the way, we are the only DAX company to have achieved this. Even so, we recognize that our responsibility as a company has grown, and society's expectations have risen as well. That is the reason we have made sustainability one of Bayer's strategic levers. One key point deserves mention here. People sometimes ask me what this emphasis on sustainability costs us. The answer is very straightforward. We plan to make money with sustainable solutions, and from where I stand, that must be the path ahead.

Werner Baumann

executive
#21

For industry to truly succeed, sustainability and profitability have to go hand in hand. That's the only way we can bring about the shift to a sustainable future. When it comes to making a tangible, measurable contribution toward achieving the United Nations Sustainable Development Goals, Bayer is better placed than many other companies, since our portfolio is fundamentally oriented toward health and nutrition, and we hold leading positions in both. This is precisely why our new sustainability targets are so specific and so ambitious. By 2030, we aim to support 100 million smallholder farmers in low- and middle-income countries by giving them access to more innovations, knowledge and partnerships. Over that same period, we intend to give 100 million women in low- and middle-income countries access to responsible family planning. We plan to accomplish this by providing financial support for aid programs and by ensuring a supply of affordable modern contraceptives. In addition, by 2030, we intend to broaden access to everyday health products for 100 million people in underserved communities worldwide. Climate protection is another area where our sustainability targets act as a driving force. We have set a specific goal for ourselves: to become 100% carbon neutral in our own operations by 2030. To get there, we will put investment into energy efficiency, move to renewable electricity and offset whatever emissions remain through biodiversity-enhancing carbon capture.

Werner Baumann

executive
#22

Meanwhile, alongside our customers and suppliers, we're collaborating across the whole value chain to cut their emissions and put sustainable solutions in place there too. In our view, agricultural innovations have an especially significant role in securing a sustainable future. We're chasing our sustainability goals as vigorously as we chase our financial ones, and so we'll ask the Annual Stockholders' Meeting in April to approve adding the sustainability target into the compensation system for the Board of Management. Our aim is to help bring about the sustainable development goals the United Nations set for 2030, in particular ensuring a healthy life for everyone and ending hunger. Health for all, hunger for none. That's the vision here at Bayer. It's the big objective we're striving toward, no matter how far off it may be. We strongly believe that our scientific know-how and our capacity for innovation let us help prevent or even cure diseases, improve people's everyday health, and feed a growing global population, all while operating sustainably. That's the thinking that will shape our company and drive it forward in the years ahead.

Werner Baumann

executive
#23

So, ladies and gentlemen, that brings me to the close of what I wanted to say. Wolfgang and I have demonstrated that the commitments we made for 2019 were honored. More than 100,000 colleagues across the globe put in tremendous effort during the past year to satisfy what our stockholders expect and what our other stakeholders in society expect. To us, both of those matter enormously. And they can keep counting on Bayer in 2020 and beyond. We mean what we state and we deliver on what we state. That holds true, most of all, for our emphasis on satisfying customers and patients, since that is what we are measured against daily, and rightly so. It holds true for carrying forward our portfolio efficiency and structural measures over the years through 2022, including the synergies we plan to achieve from the acquired business. And it holds true for making sustainability even more firmly an integral component of how we do business and for continuing to reinforce our capacity to innovate and our potential for growth. Many thanks for listening. And my colleagues and I are now happy to take your questions. Thank you.

Michael Preuss

executive
#24

Thanks a lot, Werner Baumann and Wolfgang Nickl, for those presentations. At this point you can pose questions, so please signal if you'd like to ask one. Kindly hold off until a microphone reaches you, since that lets everyone in the room hear you better and also lets colleagues joining through the webcast hear you too. We'll wrap things up no later than 11:50. That gives us over an hour for the Q&A. The first question I'm seeing comes from Ms. Weiss, at the black microphone.

Speaker

unknown
#25

I’ve got 3 questions. I understand your point that it’s hard to say anything right now about reaching a broad solution, including possibly arriving at a settlement. How could that actually be done? Glyphosate is being sold. I think you’ll tell us that you’d be walking away from business with private customers. Is that the speculation? And then, at what settlement figure would you say it stops making sense? Also, could you share any further details about the situation there?

Werner Baumann

executive
#26

Ms. Weiss, all right, I'll do my best to address your three questions. As I mentioned, we're handling this within the mediation process. We've stated repeatedly that if it's feasible, we'd like to reach a definitive resolution to this entire matter. Naturally, many different facets are at play among the various parties — issues that are currently being talked through — but given how confidential those discussions are, I'm unable to say anything about any of it at this moment. We're all aware that certain speculation has appeared in the media. And we're also aware of speculation concerning the Roundup question in the hobby and gardening segment, but as I said, I can't comment on that. The same holds true — and I hope you'll understand — the same holds true regarding any settlement amount. Speculation has been out there, but I can truly only restate what I've told you previously. At this stage, we can't comment on it. And naturally, as I said, we're in negotiations. These matters are being discussed, and that's where things stand currently. That is everything I'm able to share with you. Turning now to Elliott and to all of the other shareholders, we have been talking this through with every one of our shareholders.

Werner Baumann

executive
#27

And when it comes to individual cases, we've held one-on-one conversations, but we aren't making any specific statement here. So to put it another way, we've talked about this. There's an ongoing dialogue between us and all of our shareholders.

Michael Preuss

executive
#28

All right. Moving on to Mr. Geisler, who also has the black microphone.

Hendrik Geisler

unknown
#29

Hendrik Geisler here, from Kölner Stadt-Anzeiger. I also have 3 questions. Regarding the efficiency program, what's the situation with job reductions in Germany? I've heard that 4,500 positions are set to go. How many of those have already been implemented? And how many people have gone into partial retirement or early retirement? How many have taken up that option? My second question concerns the sustainability targets you mention. Could you tell us how far-reaching this is? What exactly will you be putting to the shareholders? What is the scale — what's the amount involved in these sustainability goals? And then Xarelto and Eylea: 37% of the pharmaceutical sales came from these 2 products. As I understand it, both patents expire in either 2025 or '26. Could you explain how you intend to offset that?

Michael Preuss

executive
#30

Okay, thanks a lot, Mr. Geisler. Wolfgang Nickl will be first to ask, and his question covers Xarelto and Eylea. Stefan Oelrich is also going to handle that one, as well as the third question.

Wolfgang Nickl

executive
#31

Alright, thank you so much for that question, Mr. Geisler, regarding the efficiency programs and where things stand. Let me give you the figure: EUR 2.6 billion in total — that's our goal, and we're performing quite well. 30% has already been achieved. That was during last year. And in the current year, we aim to reach another — altogether 50%. During the Capital Market Days, we mentioned 30% for 2020, but we're doing very well indeed. And we do expect to hit these targets. When it comes to personnel, all of the programs will come to roughly 12,000 colleagues across the globe. 4,500 of them will be located in Germany. During 2019, headcount around the world came down by approximately 4,000, and it was around 650 here in Germany. Once again, we operate worldwide, and we intend to make this as fair and socially compatible as possible. And here in Germany, naturally, we offer attractive programs. We also have a company agreement in place, and its purpose is to secure the future. It's called 2025. And this is something we want to state explicitly — that this would not be accomplished through redundancies. So the program is advancing faster than anticipated. We're very pleased.

Michael Preuss

executive
#32

Stefan, you have the floor.

Stefan Oelrich

executive
#33

Regarding Xarelto and Eylea, the progress on these 2 drugs has been really strong. During the past year, in 2019, we achieved record results for both of those products. When it comes to patent expiration, let me frame it this way: that isn't something that will occur immediately. Our expectation is that over the coming years, Xarelto and Eylea will keep delivering profitable growth. I can also share that a whole series of new products has been launched over the last 1.5 years. Four new products have come to market in oncology, as well as in hemophilia and trades such as <<inaudible>>, or Jivi for hemophilia too. So we have additional products in the pipeline for cardiovascular medicine as well. We can also see that we're in the late phase for 2 important products. A few weeks ago, we announced positive results — preliminary results — from a large Phase III study. We hope that drug will receive approval. It's a product for treating cardiac insufficiency, and we also expect data on finerenone by the end of the year. That one is for renal insufficiency, and we see great potential there.

Stefan Oelrich

executive
#34

And at the moment, this is a low therapy standard. So in earlier cardiology phases, we also have some quite promising anticoagulation products. And with Xarelto, this is an area where we've been very successful. We now have 3 products, and all 3 are in Phase II at this point. So all 3 products are in progressed clinical development, and we're very optimistic. And when it comes to oncology, we've made good progress there as well, with the launch of Nubeqa <<inaudible>>. The early results here match what we expected. And that's why we're very well positioned there. And speaking longer term, we also have some products in the early pipeline. And we've strengthened our position in business development and licensing. And there, too, we're very, very active. Last year, BlueRock was acquired, and here we'll have a cell and genetic engineering activity. This is a Boston-based company where we have some very promising first initial approaches for treating Parkinson's disease. And we hope that this year, we'll get the approval to start clinical studies. So all in all, we can sum it up by saying that patent expiration is not going to happen right away for these 2 major products.

Stefan Oelrich

executive
#35

And we still have time remaining. That time is going to be put to use. Plus, we have a few options that are quite attractive.

Michael Preuss

executive
#36

Thanks a lot, Wolfgang and Stefan.

Werner Baumann

executive
#37

On the question of how sustainability targets will be folded into our compensation program: first, for 2020 we've placed a portion of short-term remuneration into the 2030 road map. Then, starting in 2021, we will likewise incorporate a 20% contribution into the remuneration system as a performance factor for long-term remuneration. That system is going to be put forward to the Annual Stakeholders' Meeting. As for long-term remuneration, several adjustments will be made, and those will also be presented to the Annual Stockholders' Meeting. A performance factor will exist that, as of 2021, consists of 3 parts: first, relative performance of a euro stock; second, hitting specified ROCE targets — each of those carries a 40% weighting — and then a 20% weighting is proposed for meeting sustainability goals.

Michael Preuss

executive
#38

Alright. We’ll take the next questions from Ms. Höning.

Antje Höning

unknown
#39

I have three questions as well. First, regarding the job reductions: Mr. Nickl, you mentioned positions being eliminated, but my focus is on the people at the individual sites. Could you give us more specifics on how many jobs will be cut in Leverkusen, to the extent that you already know, and how the remaining reductions will be spread across Germany? Second, Mr. Baumann, we heard Mr. Wenning's announcement yesterday that he is leaving the company. So how do you feel without his support? Will things become more difficult for you going forward? And third, I would like to know about the situation at the plants in China and Italy.

Werner Baumann

executive
#40

Okay, Wolfgang, do you want to take the first question? I’ll handle the other 2.

Wolfgang Nickl

executive
#41

Yes. Well, we’ve never provided more granular detail by plant regarding the job reductions, but it’s fair to assume that locations with larger headcounts will feel the impact—Berlin and Leverkusen, for instance. As you’ve seen in IT, a certain amount of outsourcing has taken place, and that will predominantly hit Berlin and Leverkusen. In pharma as well, we’re referring to 400 colleagues, and in Berlin too. In Wuppertal, we managed to create a substantial number of new positions there in connection with the plant’s discontinuation. So yes, I hope you understand that I’m unable to share more specifics on those figures.

Werner Baumann

executive
#42

Thank you, Wolfgang. Ms. Höning, about your second question concerning Mr. Wenning as the head of the Supervisory Board, who has now announced that he will be leaving. And as you said, this is an era that is coming to an end due to the length of time that he was involved with the company and made his mark in various areas. So as of the 29th of April, we will have Professor Winkeljohann taking over for Mr. Wenning. And of course, the Board of Management has been made aware of this as well and of the new composition of the Supervisory Board. And the Supervisory Board will continue to support the Board of Management and monitor the Board of Management, and so really this is business as usual. That is the task of such a committee of the Supervisory Board, which is composed of 20 members, who each of them in their role in the Supervisory Board have a responsibility towards the owners of the company and the shareholders. Regarding the coronavirus. There was an announcement yesterday that there was a suspected infection here in Leverkusen, but Mr. Preuss has already referred to this briefly this morning, namely that this suspected case, thankfully, has not been confirmed for our colleague in China.

Werner Baumann

executive
#43

From what I understand, there's only a single case among our people. Our operations in China have been impacted, but I believe we've had just 1 instance of corona specifically there, and none in Italy.

Michael Preuss

executive
#44

Next, a question from The Wall Street Journal came in through the webcast, and it included a few questions about the coronavirus. People are worried that there could be supply issues with medicines for those in China. How would you assess that? Also — what steps will you take to counter it? And how has this affected Bayer and the business? What do you anticipate the impact could be over the months ahead?

Werner Baumann

executive
#45

Okay, Ms. Bender, let me try to address that. Like most pharmaceutical companies, we rely on materials that come from China. The real question, though, is how fast supply disruptions could hit our supply chain for these pre products, and at what point we would actually see the effects on the market — right now we are not in a position to make specific statements about that. Wolfgang Nickl already referred to this in his presentation. It is simply too early to make specific statements. Our pharma production in Beijing is running as normal. And our crop production, just to mention this incidentally as well — well, there was a slight disruption there, but since the 10th of February, that has been restored as normal. And our logistics change — chains have perhaps been affected to some extent for our consumer because one of our partners which — runs a large distribution center in the affected areas, but it is, like I say, far too early to make any specific statements on this. The situation is far too volatile at the moment. And as always, there are some negative and some positive effects here, so we will try and reflect this in the quarterly report in the first quarter in more detail, hopefully also with a better perspective for the entire year 2020.

Michael Preuss

executive
#46

All right, let's head back into the room. Ms. Dorstad, you have the blue microphone.

Speaker

unknown
#47

I've got a question about the dicamba ruling. Could you break it down for us — maybe how much of it would fall to Bayer and how much to BASF? Or is that something you still have to work out yourselves? Then, when you discussed earnings in the agricultural segment, you mentioned the dicamba plant and said there were some major problems there. What kind of plant is it? When did it open? Do you expect additional depreciation on it? You also said EUR 30 billion will be invested for the future, with 2/3 going to R&D. What will the remainder be used for? And if you can't share details on the content, perhaps you could give us a timeline for the settlement discussions. Will that happen before the shareholders' meeting, or will it take longer than that?

Werner Baumann

executive
#48

Thank you very much, Ms. Dorstad, for those questions. Let me start with dicamba. This is a first-instance judgment. And I have to say, we consider the situation that produced this incorrect ruling. We will file an appeal — our attorneys along with BASF's attorneys. The suit against us is joint. We've gone through this very carefully with our lawyers, and typically a minimum threshold must be met before a matter can go before the courts. Proof of damage is required, and as I told you earlier, that has not been provided. So the first step is that we will file post-trial motions within, let's say, the next 4 weeks. We will address that very clearly, set out our position, and then move on to the next instances. And I'm certain that as part of these discussions, there will also be discussion about — if it reaches that stage, and I want to make this very clear — the judgments, both on damages and the criminal judgments, are unsubstantiated. We and BSAF (sic) BASF will also discuss how this gets split up and talk it through. A second point on dicamba: this is a new plant that was a Monsanto plant, commissioned by Monsanto.

Werner Baumann

executive
#49

And it's still being built. It will get finished. The depreciation that's been taken is roughly $550 million, and that represents depreciation on the remaining book value. And the volumes this plant was designed for — those won't be reached. That's why — when you look at the assessment and the capacities that were factored in, that's where the depreciation came from. Last point: the EUR 30 billion of investments for the future. As you mentioned, 2/3 of that is R&D. The other 1/3 will go into intangible assets as well as plant, equipment, and property; put differently, intangible assets such as in-licensing, and so on.

Michael Preuss

executive
#50

Regarding the timeline...

Werner Baumann

executive
#51

Apologies — I overlooked that point about the timeline. During the mediation talks, we're working toward an outcome we can accept. So if we were to adopt particular deadlines and agree to particular deadlines, there's a strong chance the result would not be the best one for our company and for our shareholders. That's the reason we'll keep negotiating until we reach a result on this mediation that we find acceptable. As a result, there is no set timeline.

Michael Preuss

executive
#52

All right. The next person is Mr. Frantof at the blue microphone. I’ll read out the list. After that we have Mr. Loh, Mr. Boge, Mr. Schulter, Mr. Ackerman, Mr. Schroeder, and then Ms. Becker.

Speaker

unknown
#53

I've got a couple of questions, though a couple have already been asked, so I have 2 remaining. Regarding the annual report and glyphosate, there may be greater financial demands, and that could mean a capital increase or selling off certain assets. I only just read about that. So do you view this as a major risk, or are you simply looking into these matters? My second question concerns Mr. Strenger: you reached agreement on a special voluntary audit. Perhaps you could share some information about why you chose to proceed with it. And what result do you anticipate from this special audit?

Werner Baumann

executive
#54

Well, thank you very much. Wolfgang Nickl is going to ask — answer the first part of your question, and I will take the second part.

Wolfgang Nickl

executive
#55

Thank you, Mr. Frantof. Yes, this was a risk that came up. You need to discuss every theoretical possibility regardless of how probable it is. Naturally, we discuss certain potential payments and the manner in which they would be made. And we also — let me share some figures with you. At the Capital Market Day, we stated that across the next 4 years, '19 to '22, 2019 to '22, roughly EUR 23 billion is going to be generated in free cash flow. That is our target. That figure included Animal Health and Currenta, so it will be somewhat lower. And we also stated that we would reach this through M&A as well as by cutting debt and dividends. We have certain options for keeping this under control, but we also have substantial earnings from our divestitures. As we heard this morning, the gross proceeds from the Elanco transaction, this is variable, but it will land somewhere around EUR 9.3 billion. So we see that there is some flexibility available to us out there. And should any delays arise, for example, then naturally, we still retain the option of taking on some bridging loans. And we have banking partners, all sorts of banks that we can work with.

Werner Baumann

executive
#56

Thank you very much, Wolfgang. I want to respond to what you asked about the agreement with Mr. Strenger. A year ago — he asked for a special audit. That effort did not succeed at last year's shareholders' meeting. We talked the matter over with him and reached an arrangement, under which we would conduct a voluntary special audit. He then picked a special auditor, which was part of the contractual duties we took on. We settled on having an independent lawyer from a highly regarded U.S. law firm. An expert opinion had been prepared at the time Monsanto was acquired, concerning glufosate (sic) glyphosate. That opinion was looked at again as well, along with the 2 expert opinions prepared last year by Linklaters and Professor Habersack. As part of the Board of Management's review of due diligence, this was also done in an extended version. So that is essentially the work now under way. Initial findings from the review of the glyphosate opinion have been made available. The results of the special audit by Professor Böcking in Frankfurt are not ready yet, but we expect them within the next couple of weeks, and at that point, of course, they will be published in full.

Michael Preuss

executive
#57

All right. Our following question comes from Mr. Loh, who has the black microphone.

Tim Loh

unknown
#58

Mr. Baumann, you already touched on Werner Wenning. I just wanted to pose a question about that. What lessons have you drawn from him across the years? And looking ahead, when you work with a new person in the Supervisory Board chair, what sort of benefits do you foresee? Mr. Winkeljohann, for instance, had no part in the Monsanto acquisition.

Werner Baumann

executive
#59

Right, Mr. Loh, thanks for your question. Well, I think if you look at Mr. Wenning's CV and the full span of his career, there's a great deal that could be said, and I think we wouldn't have enough time at this press conference to go into all those details. Mr. Wenning has held lots of positions in this company. He's very familiar with our company. And as Chair of the Supervisory Board, he is very much involved in a number of different areas. And he has a very great amount of knowledge and experience in the discussions on the Supervisory Board. Of course, he was CFO, he was CEO, and he was also — this was mentioned in the press, he was also involved in corporate governance. He was a member of a number of different committees as an expert. He's also active in many other companies, Siemens, the Deutsche Bank, Henkel or even at E.ON. He has had very important positions in Supervisory Board committees. So as I said, I don't think that there are very many chairs of supervisory boards with such great experience. So we as a company benefited from him up until the very end of his term of office, up until the Annual Shareholders' Meeting.

Werner Baumann

executive
#60

Professor Winkeljohann brings a different profile. He will be the first Chairman of the Supervisory Board drawn from outside the company. The Board elects him. He takes over the chair at the close of the Annual Shareholders' Meeting. His CV shows other strengths. He ran the European organization of PwC, covering not just auditing but consulting as well. Digitalization is an area where he has deep experience. I believe we can gain from that and learn from his expertise — as we did before, but even more now. Given his management background, I am confident he will lead the Supervisory Board well, both with the shareholders' representatives and with the employees' representatives. He will make an excellent Chair, I am sure. We look forward to the new era at Bayer that starts when he assumes the chairmanship of the Supervisory Board. We are very grateful for all the years Mr. Wenning has devoted to us and to serving our company. He has stood behind every one of us throughout.

Michael Preuss

executive
#61

Our next question comes from Mr. Boge, who is also on the black microphone.

Speaker

unknown
#62

I believe most of what was asked has been addressed already. I just wanted to touch briefly on the actual debt numbers that were cited as the target for 2020. I think that was EUR 27 billion. So is that explicitly without a settlement, or might it also include one? And then second, the annual report contains an indication of a share buyback program, which was also mentioned last year. So is that a serious intention? And third, which products does Bayer have available to fight coronavirus?

Executive

executive
#63

I'll take the first 2 questions, and the third one, I believe, Stefan will handle. Yes, that assessment was accurate. The EUR 27 billion in net financing debt doesn't factor in any potential settlement. So your understanding was right. On share buybacks, at our Capital Market Day in December 2018, we stated that from the proceeds of divestments we could see share buybacks as a possibility, since we view that as an excellent investment — but we always frame this as coming after debt reduction. So we need to look at the earnings contributions to stay at the same leverage. And therefore we also have to enable this through debt reduction. We've kept this option open. Naturally, all factors have to be taken into account. If that money does arrive, we have to weigh a potential settlement and other investments. So that decision will be made at the time. Right now, I'd say it's rather improbable that we'll be doing any share buybacks soon. Stefan?

Stefan Oelrich

executive
#64

So, on how well Bayer products work against corona: we don’t currently have any medicines authorized specifically for that on the market. That said, some Bayer products could be used on top of other treatment. Take antibiotics — they’d assist patients, especially those with respiratory issues. They’d also help boost the immune system. Beyond that, Chinese authorities have already been running tests on several medicines to see whether there are extra indications not covered by their current authorizations. What’s being said there is basically experimental. That’s the only sort of statement anyone can make. From where we sit, it’s hard to comment on those statements. Through our donations, we’ve given support — for instance, with Avelox in China, a fluoroquinolone antibiotic. We’ve also helped by supplying a product normally used to prevent malaria, called Resochin. It’s a somewhat older medicine, but we ran tests with it. And some Chinese authorities said effectiveness was probable — though that should be treated with caution.

Stefan Oelrich

executive
#65

We've also been in contact with the relevant authorities here in Europe, and with hospitals here in Germany as well, to see whether that knowledge can be brought into treatment here too.

Michael Preuss

executive
#66

Thanks. At this point, we’ll turn things over to Mr. Schulter.

Speaker

unknown
#67

Yes, and I also had a question regarding any drugs Bayer might be exploring, plus any vaccines. Mr. Oelrich, you brought up a medication that isn't being manufactured anymore. Do you have any information on whether that production might restart, so it could at least serve as an additional treatment against corona? Or are you taking part in any other research programs, for instance on vaccines?

Stefan Oelrich

executive
#68

Okay, so starting with Resochin. Pakistan is the sole location where we make that product. And since it's a generic active ingredient that can be obtained from other sources as well, we chose, in looking ahead, to stop manufacturing it there. That means we really wouldn't have any remaining plants capable of making it. In China by itself, I believe we have 3 qualified production sites, and those are now increasing output of that product along with the generic version. We were the first to manage that. And we responded right away, making a special batch as well and shipping it to China. On corona, we've likewise been examining other products already in existence. It's a genuinely interesting research avenue, because this is the first occasion, so to speak, when accelerated artificial intelligence can be applied, since we're able to examine what might work in theory from a chemical standpoint. So I wouldn't describe these as entirely random hits, but we are getting a few promising hits out of our portfolio. Still, I'm quite cautious about disclosing this publicly, because we want to steer clear of any possible inappropriate treatment. So we're in discussions with the relevant responsible bodies at German hospitals and with the federal government of Germany in order to exchange and share this information.

Stefan Oelrich

executive
#69

That doesn't just hold true for Bayer — it applies equally to every other research and pharmaceutical institution and company out there.

Michael Preuss

executive
#70

Thanks a lot, Stefan. All right, moving on to the next question, which comes from Mr. Ackerman.

Speaker

unknown
#71

Martin Ackerman here, from V — WDR Studio in Wuppertal. Two weeks back, you made an announcement that you — you're looking to launch a new research institute in Berlin together with Nuvisan, bringing 400 new jobs. So what's going to happen to the pharmaceutical site in Wuppertal? Do you plan to cut capacities there? Or are they going to be kept? Or what plans do you have for the pharma research site in Wuppertal? And last year, you put up a new building for EUR 300 million. 300 employees were meant to work in it. It hasn't been taken into operation yet, so what are your plans on that front? And then on HR, again, what's the current situation at the Wuppertal and Leverkusen plants when it comes to job cuts? Well, Stefan Oelrich will take the first 2 questions, Mr. Ackerman, but on the last one, I don't think we can give you any details at a plant-based level right now.

Stefan Oelrich

executive
#72

Now, on Nuvisan and Wuppertal — first, I'm really glad we managed to get a deal arranged and agreed with Nuvisan. That's a key piece of our research, which we had initially set aside both for preserving any positions that might otherwise have been eliminated and for reinforcing our Berlin site. So it's a strong partnership that we're about to begin with Nuvisan. As for Wuppertal, the hold-ups in getting the building up and running there are very disappointing to us. This has nothing to do with any reductions in jobs. It's purely a planning delay there. So that new research building is going to open, and that highlights how confident we are, and our trust and our view of the Wuppertal plant. For Bayer, Wuppertal is the biggest research site anywhere in the world. It's also where our cardiovascular research sits. And as you may have heard earlier, we continue to place a great deal of faith in cardio going forward, and therefore in Wuppertal as well.

Michael Preuss

executive
#73

Thanks, Stefan. All right, our following question comes from Mr. Schroeder.

Speaker

unknown
#74

I'd like to hear your view on how this affects the image around glyphosate. Will it hurt the reputation, and how much? And does this help put Bayer in a position as a sustainable company? Aren't you under pressure to wrap this up as fast as possible, to reach an agreement as fast as possible? Perhaps you could also explain why no provisions are being set up for damage payments. I'd also like to know what significance glyphosate currently has for the Crop Science business. And if the approval were not extended in the EU, what kind of impact would that have? And do you have a substitute for it?

Werner Baumann

executive
#75

Thank you, Mr. Schroeder. Okay, I'll handle the first 2 questions — or at least do my best to give answers to them. After that, Wolfgang Nickl will weigh in on the matter of provisions and glyphosate, along with the EU approval and how significant glyphosate is and whether a possible substitute exists. Now, on the image question: Naturally, this is a concern for us. In certain markets, because of all the litigation and the media scrutiny we've received stemming from those lawsuits, this has, of course, affected how we're perceived and our reputation. But looking at it more closely, you'll find that this is something visible only in particular markets, and the 2 markets under discussion right now specifically are Germany and France. In other markets — a big market for us, where 9,500 employees work for us. And the — in that market, China, we ranked as the third largest company. There, over that same stretch of time, we saw our image and reputation rise and improve, while in a number of other countries or markets our image and reputation have stayed stable. That includes a market like the United States.

Werner Baumann

executive
#76

Behind you, you can see some posters from our campaign in Germany. In the foyer, you can see <<foreign_lang>>. And here, we're talking about discussing this with our employees. Why do they come here to work every day, to work in the lab or in their office or in the plant? It has very little to do with the negative aspects and the impact on our reputation. We see, and I'd just like to emphasize this point, these lawsuits are a result of the American legal system. All these lawsuits have nothing to do with safety or responsibility vis-à-vis consumers and our customers. No, these lawsuits are the result primarily of the United States legal system. And you can see this in a number of different areas worldwide. This has been a confirmation of the fact that glyphosate is a safe product. It's an independent confirmation of our position by the regulatory authorities worldwide. And our final point, the EPA, the environmental protection agency, as I said, gave us an unlimited certification of safety. That was in January of this year. So I think even the slightest doubt with regard to this assessment, this would then mean limitations in the use of the product in the gardening area.

Werner Baumann

executive
#77

No — actually, the EPA has fully confirmed where the product stands right now. So I think those 2 things have to be looked at separately here. Which leads me to your second question, on sustainability. As I explained earlier in detail, this serves as our benchmark. We honor our commitments, we act on what we state, and we state what we act on. That's why sustainability — our sustainability program, along with our targets and how they're integrated into our business strategy — is all something we will be putting into practice. And I think that, over time, we'll reach these targets and the milestones along the way through 2030. And I think all of what we do will be appreciated. Very few companies with our kinds of businesses and expertise are able to exert such a great influence on fulfilling the United Nations sustainability targets in the areas of health and nutrition. There aren't many of them out there. So, Wolfgang, over to you.

Wolfgang Nickl

executive
#78

Thanks for that question, Mr. Schroeder. I’ll address it and also get a head start on what’s likely to come next. So, regarding provisions tied to the settlement: the criteria are precisely the same ones we applied in last year’s financial accounts and at the end of the half year. You need a considerable probability, and you must be capable of estimating the amounts. And once more, together with our auditors, we have reached the conclusion that this is not a given situation. And that is also, for instance, where the EPA assessment comes into play. In other words, we still believe we have 3 years of defense costs that have been set up in provisions. That represents about 1/3 of the overall defense costs in provisions. As Mr. Baumann said, this shows you the extent of lawsuits in the United States. Now let me turn to your question. When it comes to the assessment of goodwill and impairment tests, different rules apply here. You have to consider the fair market evaluation. So you have to put yourself in somebody else’s shoes. In other words, if we take a look at other analysts and how they would assess a settlement.

Wolfgang Nickl

executive
#79

Now at this point, goodwill and impairment testing come into play. Our assumption rested on external data for an external settlement, yet no impairment resulted from it.

Executive

executive
#80

Thank you very much, Mr. Schroeder, for that question. Broadly speaking, on how much glyphosate matters to Bayer and to agriculture: we don't disclose sales figures for active ingredients, but our sales came to roughly EUR 5 billion in 2019. Of that amount, we can assume around half related to glyphosate. And within that 1/2, roughly 10% sits in Europe. That's the point you raised. You asked about how relevant it is in Europe. Now inside Europe, as you're aware, we have applied for recertification, and that has to be completed 3 years before the approval lapses, since the 15th of December 2022. So we lodged this application last December to be recertified. The complete file must be handed in by mid-June, which we will do. And this would initially go to the 4 countries that will evaluate it jointly — France, the Netherlands, Sweden and Hungary. They will evaluate the situation. And this will go to the European authority ECHA; and they will then issue a recommendation to the European Commission, which will then take the final decision. As far as we know, this is the first time in this approval process that this is being done fully transparently, as a result of an initiative which we started.

Executive

executive
#81

Every minute from every one of those meetings gets published. You'll find it across all the documents. So the general public has access — interested NGOs too, and the media. That makes this fully transparent. And our view is that, judged on scientific criteria, approval or reapproval will clearly have to follow. You asked what happens should reapproval not come through, if the license isn't granted, if — are there alternatives? Well, what we're discussing here is weed management. Alternatives always exist. The real question is whether they're any better. Safer? More effective? More sustainable? We — the whole industry — have spent many years researching this, seeking something superior to glyphosate. To date, nothing has turned up that is safer, more effective and more sustainable. When it comes to investment, versus all the other companies, ours has been larger — far larger — on weed research, exceeding every other manufacturer. As you know, EUR 5 billion is to be invested over the next few years, and a number of new formulations will be studied. I believe it was last week or the week before last when we announced that the new effect for weed management has been determined or discovered.

Executive

executive
#82

This is still at a really early stage of development at the moment, but it marks the first time in 30 years that we've developed a new effect. And now we need to work through all the relevant studies — toxicology, environment, health, et cetera. All of those tests have to be done. It will definitely take another 10 years before a product like this can be launched. And whether it's better than glyphosate or complementary to it, that's something we'll find out over the course of these studies.

Michael Preuss

executive
#83

Okay. So — at this point we have Ms. Becker, Ms. Jansen, Ms. Kroesteman, Mr. Tosi and Mr. Geisler joining us. And we'll figure out how to handle this in terms of time. Like I mentioned, from 10 to 12:00, we need to wrap up, but let's start with Ms. Becker.

Speaker

unknown
#84

Sure, I’ll keep this short. I’d like to ask about the BASF litigation. Could you share more details on that arbitration? You mentioned, Mr. Nickl, the IFRS 16 regulation. Can you explain how it impacted the 2019 annual report? Then on your forecast: in your annual report you stated what you expect for the market. So why are Pharmaceuticals and Consumer Health performing below the market expectation?

Werner Baumann

executive
#85

Thank you, Ms. Becker. I'd like to touch briefly on the arbitration, and then Wolfgang Nickl will take your other questions. So, with BASF, we hold different views concerning any securities that are contractually established and also concerning any divestments under antitrust law. And these matters could not be foreseen in advance. And so far in our talks, we ultimately have not arrived at a shared position on how these perspectives should be handled. And given that, these arbitration proceedings were launched, as was set out in the contracts. And we have had the first — well, the first oral proceedings will not happen until the middle of 2021.

Wolfgang Nickl

executive
#86

Okay, turning to the much-loved IFRS 16. As you’re aware, that relates to operating leases, and I mentioned an impact of roughly EUR 1 billion on our results. The EBITDA impact was also built into the guidance we gave at the start of the year, and we spoke about EUR 370 million. So on market development, we have guidance for Consumer Health. We’re very pleased with the 2.6% growth last year. We initially said we would aim for 1%. And at the Capital Markets Day, we said we didn’t — we wouldn’t catch up with market development. We actually had the 2022 target with peers, and we did succeed on that last year. So when we look at our figures, we’re around #2 among the top 7. And we’re very pleased with that indeed, and I think we can build on it. The 2% to 3% forecasts for 2020 sit very much within our road map. The same holds for Pharmaceuticals. Last year, we had about 4% to 5% for the 2019 to 2022 period, and we now have 5.6%, so that’s actually somewhat better — quite a lot better. And for 2020, we’re mainly looking at growth in China, which will be around 25%, and that will result in price changes and tendering and so on and so forth.

Wolfgang Nickl

executive
#87

As I mentioned, we are right on track with what we laid out at the Capital Markets Day.

Michael Preuss

executive
#88

Thanks, Wolfgang. Moving on to the following question, which comes from Mr. Jansen.

Jonas Jansen

unknown
#89

To clarify something about glyphosate and what the annual report says — give me a second while I locate that specific passage. Right, it concerns the divestment of assets. So in a worst-worst case, what exactly would be divested in that worst case? And then, on Essure, there's a reference to accounting provisions tied to claims under existing insurance protection for Essure and Roundup. So I was wondering what this actually points to here — these accounting provisions. Is that referring to the EUR 1.2 billion? Probably not.

Wolfgang Nickl

executive
#90

Okay, so on your first question — yes, you've got that right. Like I mentioned before, we're looking at every possibility, even where the odds of those things happening are extremely low. In the ordinary course of business, we do sell assets when we no longer need a building, that kind of thing, but that's simply day-to-day business. Beyond that, though, we have no additional divestment plans. And then I mentioned EUR 1.2 billion — I believe that's appendix 23 — EUR 1.2 billion in total as a setback for defense costs. So I think roughly 30% of that relates to glyphosate. The remainder covers other litigations, pending litigations, where we have to defend ourselves, but we have no further provisions past that. And anything else — nothing further can be found in the annual report beyond that.

Michael Preuss

executive
#91

Alright, we'll take the next questions from the other side of the room, starting with Ms. Kroesteman.

Speaker

unknown
#92

Sure, I’d like to ask about the new products you mentioned. You said you expect sales growth in your agriculture business from new products in 2020. Could you possibly elaborate on those new products, especially in Europe, and on the expected sales growth? What contribution will these products make to sales in the agriculture business?

Executive

executive
#93

Yes. Thank you, Ms. Kroesteman. So for 2020, sales growth in the crop business is going to come from 2 main regions. One is North America, which will be driven simply by an increase in acres, or by a return of the acres that weren't planted last year. We expect between 10 million and 12 million additional acres there, and we'll benefit particularly from our corn and — I'm sorry, corn seed and trait business, and also to a degree from soybeans. And Latin America will keep going, particularly with our fungicide business and our soybean business. In Europe, we do expect growth to continue, but on a significantly smaller basis than what we expect from North America. And here the drivers are more in the insecticide space. And we have 2 new insecticides on the market, particularly in the fruit and vegetables space, that are being rolled out. And otherwise, on fungicides, that would be kind of the main areas. What's also growing particularly strongly in Europe, and grew last year and is forecast to grow again this year, will be our corn seed business, which is more relevant for East Europe.

Michael Preuss

executive
#94

Since we’re already in English, we have a single follow-up question that came in through the webcast. It’s from Luenzo Tosi with new business media in Italy, and it concerns the reregistration of glyphosate in Europe. Do you believe the EPA’s evaluation of the herbicide glyphosates — which reaffirms that there is no risk to public health — will have a decisive influence on the registration process for this product in the United States, or even in Europe?

Executive

executive
#95

It certainly doesn’t hurt. Whether it truly provides a benefit, I honestly can’t say. My expectation is that the scientific authorities in Europe will reach their own conclusion by reviewing all the data submitted that is relevant for Europe. That said, I’m fairly confident they’ll also take into account what regulators elsewhere in the world are saying. Ultimately, though, they will arrive at their own judgment.

Michael Preuss

executive
#96

Alright, so I believe Mr. Geisler has a question for us.

Hendrik Geisler

unknown
#97

So just a question on the sustainability goals — I was taking a look at these. And Mr. Berninger, at last year's "future for farming" congress, you said about the sustainability goals that sustainability would be given equal importance to financial factors. But the figures don't reflect that if you're only talking about 20%. So could you explain why this decision was made? And then a second question, about the Annual Shareholders' Meeting of 2019 — it's almost a year ago now. Mr. Baumann, what impact did that decision have, that you were not dismissed? Could you explain a bit about that?

Werner Baumann

executive
#98

Well, thank you. Regarding your first question, the sustainability goals form a core component of our business strategy and sit on equal footing with our financial targets. So when it comes to Mr. Berninger's statement — he's seated behind you — I can only concur, and I do so on behalf of the other Board of Management members as well. Then the question becomes how we will handle the incentive measures and how those will be structured. The Supervisory Board has sought considerable input from outside organizations. And it matters a great deal to all of us that the sustainability goals also find expression within our remuneration systems and are firmly anchored there. So to begin with, these are long-term targets. And naturally, this constitutes the major, the primary portion of our remuneration system. So it's very important that this is mirrored. Now the 20% built into the performance factor can, of course, be deliberated further. And the Supervisory Board along with the Remuneration Committee have engaged in quite intensive negotiations on how all of this will ultimately be determined. And this will be put before the Annual Shareholders' Meeting for their approval, so we shall see how they rule on it.

Werner Baumann

executive
#99

There isn't a correct or incorrect approach here. What matters most is that this gets enshrined in some form. Second, on how this is weighted over the long term, I think you can take it that what Mr. Berninger stated, and what I have confirmed for the Board, is that this will be decisive in how we run the business day to day. On your second question about the ratifications at last year's Annual Shareholders' Meeting: I completely understand — and I said so at the time — that our owners ultimately were maybe not pleased with how things were developing given the losses, and perhaps also as a result of the glyphosate decisions, in that there were serious doubts about whether due diligence had been satisfied and whether we had truly assessed the risks properly, including when preparing the acquisition. So that vote is something I can comprehend. As for whether I was especially happy about it, I think that is obvious. Naturally I wasn't, but that was the shareholders' vote and we must accept it. And I think it mattered at the time, for me and the other Board members, that the Supervisory Board also clarified whether we had met our due diligence obligations.

Werner Baumann

executive
#100

And we — there were several statements given there, 2 independent statements that were accessible in a brief form at the Annual Shareholders' Meeting. And I've mentioned at another point that, had we not fulfilled our tasks, then of course I wouldn't be able to stay in my position. That responsibility would have been too large. So those are the effects on the company. And they're temporary in nature, clearly. And that takes us back to the topic of processing the glyphosate litigations. And the impact from that was simply too great last year.

Michael Preuss

executive
#101

All right, we’ve got one last question coming in via the webcast. This final set of questions goes to Stefan Oelrich from Hélène Mauduit at Health Europe. So, in English. On the pharma side, which new launches and indication extensions for products that are already approved should we expect in 2020 — vericiguat and finerenone? Stivarga appears to have bounced back from the flat sales seen in 2018. So how do you view the situation at this point? And the last one is that Xofigo is no longer among the best-selling products listed for 2019. Is its commercial future being held back?

Stefan Oelrich

executive
#102

All right, let's begin with the launches we have planned for this year. We anticipate filing vericiguat for approval at some point during this year. Depending on how quickly regulators act, the launch would land more in '21 than in 2020. The indication we'll be submitting in is most likely heart failure in patients with reduced ejection fraction. On finerenone, we're awaiting the conclusion of our pivotal trial — that should wrap up in the first half of this year. Top line data should come somewhere in the second or third quarter of this year, depending on how quickly we finalize things; we could then hope to submit for regulatory approval in the first countries at the end of this year or the start of next year, which would also point to a launch in '21. As for launches this year: in oncology, we're bringing forward — following a positive CHMP opinion, we expect regulatory decisions for Nubeqa in Europe; and after that a European launch, which would give you the Europe launch this year. Then the second question concerned Stivarga. We're indeed very pleased with how Stivarga has developed, and that's mainly driven by very strong demand coming out of China.

Stefan Oelrich

executive
#103

We anticipate that this demand will stay robust. And finally, regarding Xofigo: it's true that Xofigo hasn't quite lived up to what we expected. That said, it's still a very valid therapeutic option for patients with advanced metastasized prostate cancer — in the bones of patients. So we still view it as probably the best option for those patients, but some combination that was tested in the past, which didn't show a therapeutic benefit but rather the opposite, led to more cautious use of the drug, which explains why it isn't as successful overall as we would have projected at the start.

Michael Preuss

executive
#104

All right, thank you so much. I believe we're just about right on schedule. Thanks to everyone for joining us. We appreciate you taking the time to be here for the news conference and for following along on the webcast. A recording of this will be available on the Internet this afternoon as well. And I hope you all have a wonderful day and stay well. Thank you so much.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Bayer Aktiengesellschaft transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Bayer Aktiengesellschaft earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Bayer Aktiengesellschaft or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.